Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Mint10d
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from ... she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave ...
Investing10d
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE:NVO ... brain fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can't leave bed.
Free Malaysia Today10d
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors ... fatigue and brain fog she experiences in the 24 hours after her weekly CagriSema injection are so bad that she sometimes can’t leave bed.
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Yahoo Finance11d
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO) is under pressure ... Novo stock slipped 1% before the bell on Tuesday. Novo believes CagriSema could be more powerful than its blockbuster ...